Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 79INDUSTRY 24FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 2Lung Neoplasms 2Urinary Bladder Neoplasms 1Patient Compliance 1Neoplasms 1Neoplasm Metastasis 1Lung Diseases, Obstructive 1Kidney Diseases 1Keratosis, Actinic 1Glioma 1Glioblastoma 1Dementia 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1

Interventions

enzalutamide 1apalutamide 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × FED × Neoplasm Metastasis × Clear all
NCT05422911 2022-06-21

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

James J. Peters Veterans Affairs Medical Center

Phase 2 Not yet recruiting
200 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡